Suppr超能文献

间充质干细胞在不同疾病患者中的递送:多模态追踪、安全性和未来应用。

Mesenchymal Stem Cells Delivery in Individuals with Different Pathologies: Multimodal Tracking, Safety and Future Applications.

机构信息

Instituto Aragonés de Ciencias de la Salud/IIS Aragón, 50009 Zaragoza, Spain.

Institut de Pharmacologie Moléculaire et Cellulaire, INSERM, CNRS, Université Côte d'Azur, 06560 Valbonne, France.

出版信息

Int J Mol Sci. 2022 Jan 31;23(3):1682. doi: 10.3390/ijms23031682.

Abstract

Due to their ease of isolation and their properties, mesenchymal stem cells (MSCs) have been widely investigated. MSCs have been proved capable of migration towards areas of inflammation, including tumors. Therefore, they have been suggested as vectors to carry therapies, specifically to neoplasias. As most of the individuals joining clinical trials that use MSCs for cancer and other pathologies are carefully recruited and do not suffer from other diseases, here we decided to study the safety and application of iv-injected MSCs in animals simultaneously induced with different inflammatory pathologies (diabetes, wound healing and tumors). We studied this by and approaches using different gene reporters (GFP, hNIS, and f-Luc) and non-invasive techniques (PET, BLI, or fluorescence). Our results found that MSCs reached different organs depending on the previously induced pathology. Moreover, we evaluated the property of MSCs to target tumors as vectors to deliver adenoviruses, including the interaction between tumor microenvironment and MSCs on their arrival. Mechanisms such as transdifferentiation, MSC fusion with cells, or paracrine processes after MSCs homing were studied, increasing the knowledge and safety of this new therapy for cancer.

摘要

由于间充质干细胞 (MSCs) 易于分离且具有特性,因此受到了广泛的研究。已经证明 MSCs 能够迁移到炎症区域,包括肿瘤。因此,它们被提议作为载体来携带治疗方法,特别是针对肿瘤。由于大多数参加使用 MSCs 治疗癌症和其他病理的临床试验的个体都是经过精心招募的,并且没有患有其他疾病,因此我们决定在同时患有不同炎症性疾病(糖尿病、伤口愈合和肿瘤)的动物中研究静脉注射 MSCs 的安全性和应用。我们通过使用不同基因报告基因(GFP、hNIS 和 f-Luc)和非侵入性技术(PET、BLI 或荧光)的 [和] 方法进行了这项研究。我们的研究结果发现,MSCs 根据先前诱导的病理到达不同的器官。此外,我们评估了 MSCs 作为载体靶向肿瘤以递送腺病毒的特性,包括肿瘤微环境与 MSCs 到达后的相互作用。研究了转分化、MSC 与细胞融合或 MSC 归巢后的旁分泌过程等机制,增加了这种癌症新疗法的知识和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6ef/8835939/0d5d52d886aa/ijms-23-01682-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验